Supernus Pharmaceuticals, Inc. (SUPN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Rockville, MD, United States. Der aktuelle CEO ist Jack A. Khattar.
SUPN hat IPO-Datum 2012-05-01, 674 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $2.89B.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, specializing in the development and commercialization of central nervous system (CNS) disease treatments. The company's commercial portfolio includes Trokendi XR and Oxtellar XR for epilepsy and migraine management, Qelbree for pediatric ADHD, and several Parkinson's disease treatments including APOKYN, XADAGO, GOCOVRI, and Osmolex ER, as well as MYOBLOC for cervical dystonia and sialorrhea. Beyond its marketed products, Supernus maintains a pipeline of investigational candidates at various clinical stages, including SPN-830 for Parkinson's disease, SPN-817 for severe epilepsy, and SPN-820 for treatment-resistant depression. The company distributes its products through pharmaceutical wholesalers, specialty pharmacies, and distributors across the United States.
